NCT04662736

Brief Summary

the aim of the study is to describe the management and outcome of patients having an osteo-articular infection treated by tedizolid as a suppressive antibiotic therapy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
17

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Feb 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 25, 2020

Completed
15 days until next milestone

First Posted

Study publicly available on registry

December 10, 2020

Completed
2 months until next milestone

Study Start

First participant enrolled

February 1, 2021

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2021

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2021

Completed
Last Updated

June 21, 2021

Status Verified

June 1, 2021

Enrollment Period

Same day

First QC Date

November 25, 2020

Last Update Submit

June 15, 2021

Conditions

Bone and Joint Infection

Keywords

bone and joint infectiontedizolidsuppressive antibiotic therapy

Outcome Measures

Primary Outcomes (5)

  • rate of patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic therapy

    proportion of patients having tedizolid as a suppressive antibiotic therapy

    between 2016 and 2021

  • rate of failure in patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic

    proportion of patients having a failure under tedizolid as a suppressive antibiotic therapy

    2 years

  • rate of adverse event in patients having had a BJI/PJI treated with tedizolid as a suppressive

    proportion of patients having a adverse event under tedizolid as a suppressive antibiotic therapy

    through study completion, an average of 1 year

  • Description of patients having had a BJI/PJI treated with tedizolid as a suppressive

    type of patients: age, CMI, comorbidities...

    2 years

  • Description of BJI/PJI treated with tedizolid as a suppressive

    implant or prothese or not, acute/ chronic, bacteriology

    2 years

Study Arms (1)

patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic therapy

Other: patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic therapy

Interventions

patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic therapyOTHER

description of osteo-articular infection managed with tedizolid as a suppressive antibiotic therapy

patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic therapy

Eligibility Criteria

Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patients having an osteo-articular infection treated with tedizolid as a suppressive antibiotic therapy managed at the CRIOAc LYON, Croix-Rousse Hospital

You may qualify if:

  • patients having an osteo-articular infection treated with tedizolid as a suppressive antibiotic therapy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospices Civils de Lyon

Lyon, 69004, France

Location

Related Links

MeSH Terms

Interventions

tedizolid

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 25, 2020

First Posted

December 10, 2020

Study Start

February 1, 2021

Primary Completion

February 1, 2021

Study Completion

April 1, 2021

Last Updated

June 21, 2021

Record last verified: 2021-06

Locations

FR(1)